Target intelligence / Profile preview

Stomatin-like protein 2, mitochondrial (STOML2)

Target
STOML2
Molecular classification
Other (mitochondrial membrane protein), SPFH superfamily, mitochondrial membrane organizer
01

Overview

Stomatin-like protein 2, mitochondrial (STOML2) is a mitochondrial inner membrane protein that functions as an organizer of membrane microdomains by binding the phospholipid cardiolipin and recruiting prohibitin complexes. It plays a vital role in mitochondrial biogenesis, the assembly and stability of respiratory complexes, and the regulation of mitochondrial quality control pathways including modulation of the PARL/PINK1 mitophagy axis. STOML2 may also localize to the plasma membrane of activated T cells, where it enhances T cell receptor (TCR) signal transduction. Aberrant STOML2 expression is seen in multiple cancer types, where its levels can influence cell proliferation, mitochondrial dynamics, apoptotic resistance, and chemoresistance—making it a proposed biomarker and therapeutic target for certain tumors. No approved drugs currently target STOML2 directly, but research highlights its potential value in cancer therapy, particularly for overcoming chemoresistance through modulation of mitochondrial processes.

Other names
Stomatin-like protein 2, mitochondrialSTOML2SLP2HSPC108Paratarg-7SLP-2EPB72-like protein 2Paraprotein target 7EPB72-like 2stomatin (EPB72)-like 2
02

Mechanism of action

Potential future anti-cancer therapies under investigation aim to overexpress STOML2 to repress mitophagy and reduce chemoresistance to agents like gemcitabine

03

Biological functions

Mitochondria organization and biogenesisCardiolipin binding and membrane domain organizationRegulation of mitochondrial dynamics, morphology, and quality controlProtein complex oligomerizationModulation of T-cell activation and signalingRegulation of calcium ion homeostasis
04

Disease associations

Cancer (overexpression in multiple tumor types: pancreatic, breast, endometrial, liver, ovarian, colorectal, head and neck)Immunological disorders (modulating T cell activation)
05

Safety considerations

Not established in clinical settings; theoretical concerns could arise from manipulating mitochondrial function or T cell signaling broadly.
06

Interacting drugs

None directly established; research explores targeting STOML2 for sensitizing tumors to chemotherapy (e.g., gemcitabine)
07

Biomarkers

Prognostic marker for several cancers (e.g., pancreatic cancer patient survival and chemoresistance)

Beyond the preview

Go deeper on Stomatin-like protein 2, mitochondrial (STOML2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stomatin-like protein 2, mitochondrial (STOML2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call